Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

February 26, 2021February 26, 2021

Single PHA121 Dose Can Block Bradykinin Effects in Healthy Volunteers

News

A single dose of PHA121 (PHA-022121), Pharvaris’ investigational therapy for hereditary angioedema (HAE), is safe and can rapidly and sustainably block bradykinin-induced changes in blood parameters, according to two studies ... Read more

November 30, 2020November 30, 2020

Injectable Preventive Treatments Weigh on Patients and Caregivers, Surveys Show

News

Routine injectable treatments to prevent hereditary angioedema (HAE) attacks place a large burden on patients and their caregivers, a survey study has found. Surveyed patients and doctors also agreed that ... Read more

October 2, 2020October 2, 2020

Children 6 and Older Can Use Haegarda to Prevent HAE Attacks, FDA Says

News

The U.S. Food and Drug Administration (FDA) has extended the use of Haegarda, a C1-INH replacement medication, as a routine treatment to prevent hereditary angioedema (HAE) attacks in children ages ... Read more

December 30, 2019January 16, 2020

Excessive Bradykinin Due to Troubled Enzyme Root Cause of HAE with Normal C1-INH, Study Says

News

The lack of control of a key enzyme associated with the overproduction of bradykinin seems to be the common root cause of all forms of hereditary angioedema with normal C1-inhibitor activity, ... Read more

December 18, 2019January 22, 2020

KVD001 Protects DME Patients From Losing Their Vision, Phase 2 Trial Shows

News

KVD001 safely protects people with diabetic macular edema from losing their vision, according to a Phase 2 trial conducted by the treatment’s developer, KalVista Pharmaceuticals. DME is a form of angioedema ... Read more

December 4, 2019January 15, 2020

CDEC Recommends Reimbursement of Takhzyro in Canada as Preventive Treatment for HAE Attacks

News

The Canadian Drug Expert Committee (CDEC) has recommended that Takhzyro (lanadelumb) be reimbursed by public drug plans when used as a preventive treatment for hereditary angioedema (HAE) attacks in patients ... Read more

September 26, 2019

NICE Recommends Takhzyro as Preventive Treatment for HAE Attacks

News

The National Institute for Health and Clinical Excellence (NICE) has recommended Takhzyro (lanadelumb) as a preventive treatment for hereditary angioedema (HAE) attacks in patients 12 and older, under certain conditions. ... Read more

September 19, 2019

Preventative Haegarda Therapy Quickly Reduces Number of HAE Attacks, Trial Analysis Shows

News

Prophylactic, or preventive treatment with Haegarda quickly reduced the number of attacks — sudden episodes of swelling — in people with hereditary angioedema (HAE) caused by C1-inhibitor deficiency, an exploratory ... Read more

July 11, 2019

Ruconest Can Safely and Effectively Treat Acute HAE Attacks in Children, Phase 2 Trial Shows

News

A single dose of Ruconest (conestat alfa) was sufficient to rapidly and safely treat almost 96% of all acute attacks in a group of children with hereditary angioedema (HAE), Phase ... Read more